76 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
it to focus on long-term planning intended to enhance stockholder value.
Set forth below are the names of and certain information for each member of our board … company is managed for the long-term benefit of stockholders. This section describes key corporate governance guidelines and practices that our board
8-K
EX-1.1
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
4:59pm
incentive plans, as described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus) or long-term debt of the Company or any
424B5
f3cyw7uot7kzrcm2i sf
19 Dec 23
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
44w7vi4o70jlwxytk
12 Dec 22
Regulation FD Disclosure
7:48am
8-K/A
EX-99.3
4n3z9
30 Nov 22
Financial Statements and Exhibits
6:46pm
425
m0k2 vqbid86vcm2c
2 Sep 22
Business combination disclosure
4:03pm
8-K
tyg35
2 Sep 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
424B3
aom lcylp
8 Aug 22
Prospectus supplement
5:47pm
S-4
65nw46h72r0n
18 Jul 22
Registration of securities issued in business combination transactions
7:58am